Claims
- 1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, 8, 11, and 14.
- 2. An isolated polynucleotide encoding a polypeptide with biological activity, said polynucleotide having greater than 98% sequence identity with the polynucleotide of SEQ ID NO: 2.
- 3. The polynucleotide encoding the polypeptide of SEQ ID NO: 16.
- 4. The polynucleotide of claim 1 which is a DNA sequence.
- 5. An isolated polynucleotide which comprises the complement of the polynucleotide of claim 1.
- 6. A vector comprising the polynucleotide of claim 1.
- 7. An expression vector comprising the polynucleotide of claim 1.
- 8. A host cell genetically engineered to comprise the polynucleotide of claim 1.
- 9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.
- 10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of a polypeptide encoded by any one of the polynucleotides of claim 1.
- 11. A composition comprising the polypeptide of claim 10 and a carrier.
- 12. An antibody that specifically binds to SEQ ID NO: 3.
- 13. An antibody that specifically binds to SEQ ID NO: 9.
- 14. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.
- 15. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions; b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and c) detecting said product and thereby the polynucleotide of claim 1 in the sample.
- 16. The method of claim 15, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.
- 17. A method for detecting the polypeptide of claim 10 in a sample, comprising:
a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.
- 18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.
- 19. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.
- 20. A method of producing the polypeptide of claim 10, comprising, a) culturing a host cell comprising a polynucleotide sequence selected from the group consisting of a polynucleotide sequence of SEQ ID NO: 2, 8, 11, and 14, an active domain coding portion of SEQ ID NO: 2, 8, 11, and 14, complementary sequences thereof, under conditions sufficient to express the polypeptide in said cell; and
b) isolating the polypeptide from the cell culture or cells of step (a).
- 21. An isolated polypeptide comprising an amino acid sequence which is at least 98% identical to the amino acid sequence of SEQ ID NO: 3, or the active domain thereof.
- 22. An isolated polypeptide selected from the group consisting of SEQ ID NO: 3, 9, 12, or 15.
- 23. The polypeptide of claim 21 or 22 wherein the polypeptide is provided on a polypeptide array.
- 24. A polypeptide comprising the polypeptide of SEQ ID NO: 16.
- 25. A collection of polynucleotides, wherein the collection comprising the sequence information of at least one of SEQ ID NO: 2, 8, 11, or 14.
- 26. The collection of claim 25, wherein the collection is provided on a nucleic acid array.
- 27. The collection of claim 26, wherein the array detects full-matches to any one of the polynucleotides in the collection.
- 28. The collection of claim 26, wherein the array detects mismatches to any one of the polynucleotides in the collection.
- 29. The collection of claim 25, wherein the collection is provided in a computer-readable format.
- 30. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising a polypeptide of claim 10 or 22 and a pharmaceutically acceptable carrier.
- 31. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising an antibody that specifically binds to a polypeptide of claim 10 or 22 and a pharmaceutically acceptable carrier.
- 32. A pharmaceutical composition comprising an anti-DCAL-Hy antibody, wherein said antibody specifically binds to a polypeptide having an amino acid sequence of SEQ ID. NO: 3, 6, 9, 12, or 15, or the extracellular portion thereof.
- 33. The pharmaceutical composition of claim 32, wherein said antibody is a monoclonal anti-DCAL-Hy antibody that is specific for a B-cell neoplasm.
- 34. The pharmaceutical composition of claim 32, wherein said antibody is administered in an amount effective to kill or inhibit the growth of cells that cause a B-cell neoplasm.
- 35. A method of targeting DCAL-Hy protein on cells that cause a B-cell neoplasm, comprising the step of administering a composition to said cells in an amount effective to target said DCAL-Hy-expressing cells, wherein said composition is an anti-DCAL-Hy antibody that specifically binds to a polypeptide having an amino acid sequence of SEQ ID NO: 3, 6, 9, 12, or 15, or the extracellular portion thereof.
- 36. A method of targeting DCAL-Hy protein on cells that cause a B-cell lymphoma or a follicular lymphoma.
- 37. A method of killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cancer cells, wherein said composition is an anti-DCAL-Hy antibody that specifically binds to a polypeptide having an amino acid sequence of SEQ ID. NO: 3, 6, 9, 12, or 15, or the extrtacellular portion thereof.
- 38. A method of killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a cancer, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cancer cells, wherein said composition comprises an anti-DCAL-Hy antibody that specifically binds to a polypeptide having an amino acid sequence of SEQ ID NO: 3, 6, 9, 12, or 15, or the extracellular portion thereof.
- 39. A method of killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm, comprising the step of administering a vaccine to said cells in an amount effective to kill or inhibit the growth of said cancer cells, wherein said vaccine comprises a DCAL-Hy polypeptide having an amino acid sequence of SEQ ID NO: 3, 6, 9, 12, or 15, or immunogenic fragment thereof.
- 40. A method of killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cancer cells, wherein said composition comprises a nucleic acid of SEQ ID NO: 2, 5, 8, 11, or 14 encoding DCAL-Hy polypeptides, or immunogenic fragment thereof, within a recombinant vector.
- 41. A method of killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cancer cells, wherein said composition comprises an antigen-presenting cell comprising a nucleic acid of SEQ ID NO: 2, 5, 8, 11, or 14 encoding DCAL-Hy polypeptides, or immunogenic fragment thereof, within a recombinant vector.
- 42. The method according to claims 35, 36, 37, 39, 40 or 41, wherein said cells are contacted with as second therapeutic agent.
- 43. The method according to claim 35, 36 or 37, wherein said anti-DCAL-Hy antibody composition is administered in an amount effective to achieve a dosage range from about 0.1 to about 10 mg/kg body weight.
- 44. The method according to claims 35, 36, 37, 39, 40 or 41, wherein said pharmaceutical composition is administered in a sterile preparation together with a pharmaceutically acceptable carrier therefore.
- 45. A method of diagnosing a B-cell neoplasm comprising the steps of:
detecting or measuring the expression of DCAL-Hy protein on a cell; and comparing said expression to a standard indicative of cancer.
- 46. The method according to claim 45, wherein said expression is DCAL-Hy mRNA expression.
- 47. The method according to claim 45, wherein said expression is detected or measured using anti-DCAL-Hy antibodies.
- 48. Use of an anti-DCAL-Hy antibody in preparation of a medicament for killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm, wherein said antibody specifically binds to a polypeptide having the amino acid sequence of SEQ ID NO: 3, 6, 9, 12, or 15, or extracellular portion thereof.
- 49. Use of a polypeptide having an amino acid sequence of SEQ ID NO: 3, 6, 9, 12, or 15 in preparation of a vaccine for killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm.
- 50. Use of a nucleic acid of SEQ ID NO: 2, 5, 8, 11, or 14 encoding DCAL-Hy polypeptides or immunogenic fragment thereof, within a recombinant vector, in preparation of a medicament for killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm.
- 51. Use of an antigen-presenting cell comprising a nucleic acid of SEQ ID NO: 2, 5, 8, 11, or 14 encoding DCAL-Hy polypeptides or immunogenic fragment thereof, within a recombinant vector, in preparation of a medicament for killing or inhibiting the growth of DCAL-Hy-expressing cells that cause a B-cell neoplasm.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/799,451 filed on Mar. 5, 2001, entitled “Novel Nucleic Acids and Polypeptides”, Attorney Docket No. 803. This and all other U.S. Patents and Patent Applications cited herein are hereby incorporated by reference in their entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09799451 |
Mar 2001 |
US |
Child |
10379127 |
Mar 2003 |
US |